Specifically, mutation clusters in RAS/RAF genes are as high as 50% in newly diagnosed MM, rising even to 80% in RRMM, underscoring the promising potential of the RAS/RAF/MEK/ERK signaling pathway–directed therapy (Podar and Leleu, 2021). This evidence concerns the gene MAP2K7 and Miyoshi myopathy.